UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways

The EMBO journal, 1998-02, Vol.17 (4), p.1006-1018

1998

Volltextzugriff (PDF)

FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)

Leukemia, 2006-11, Vol.20 (11), p.2008-2014

2006

Volltextzugriff (PDF)

dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2008-04, Vol.10 (4), p.293-300

2008

Volltextzugriff (PDF)

Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal

Cytotherapy (Oxford, England), 2004-08, Vol.6 (4), p.328-336

2004

Volltextzugriff (PDF)

Optical imaging of bilingual cortical representations. Case report

Journal of neurosurgery, 2000-10, Vol.93 (4), p.676-681

2000

Volltextzugriff (PDF)

Interleukin‐3, granulocyte‐macrophage colony stimulating factor and interleukin‐5 transduce signals through two STAT5 homologs

The EMBO journal, 1995-03, Vol.14 (6), p.1166-1175

1995

Volltextzugriff (PDF)

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial

Diabetes, obesity & metabolism, 2010-04, Vol.12 (4), p.348-355

2010

Volltextzugriff (PDF)

Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5

Journal of leukocyte biology, 1995-05, Vol.57 (5), p.799-803

1995

Volltextzugriff (PDF)

Signaling Pathways Activated in a Unique Mast Cell Line Where Interleukin-3 Supports Survival and Stem Cell Factor Is Required for a Proliferative Response

Blood, 1996-05, Vol.87 (9), p.3655-3668

1996

Volltextzugriff (PDF)

Characterization of optical intrinsic signals and blood volume during cortical spreading depression

Neuroreport, 2000-07, Vol.11 (10), p.2121-2125

2000

Volltextzugriff (PDF)

Optical intrinsic signal imaging in a rodent seizure model

Neurology, 2000-07, Vol.55 (2), p.312-315

2000

Volltextzugriff (PDF)

Purinoceptor activation of chloride transport in cystic fibrosis and CFTR‐transfected pancreatic cell lines

British journal of pharmacology, 1998-08, Vol.124 (8), p.1597-1606

1998

Volltextzugriff (PDF)

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

Leukemia research, 2004-07, Vol.28 (7), p.679-689

2004

Volltextzugriff (PDF)

Investigation of the Molecular Mechanisms Underlying Growth Factor Synergy: The Role of ERK 2 Activation in Synergy

Growth factors (Chur, Switzerland), 1998, Vol.15 (4), p.293-306

1998

Volltextzugriff (PDF)

Self-consciousness and the Psoriatic Personality: Considering Updike and Potter

Literature and medicine, 2001, Vol.20 (2), p.133-150

O'Farrell, Mary Ann

2001

Volltextzugriff (PDF)

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Blood, 2003-05, Vol.101 (9), p.3597-3605

2003

Volltextzugriff (PDF)

A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12R beta 1 and a Novel Cytokine Receptor Subunit, IL-23R

The Journal of immunology (1950), 2002-06, Vol.168 (11), p.5699-5708

2002

Volltextzugriff (PDF)

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients

Clinical cancer research, 2003-11, Vol.9 (15), p.5465-5476

2003

Volltextzugriff (PDF)

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Blood, 2003-10, Vol.102 (8), p.2763-2767

2003

Volltextzugriff (PDF)

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

Blood, 2004-12, Vol.104 (13), p.4202-4209

2004

Volltextzugriff (PDF)

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Clinical & experimental metastasis, 2003-01, Vol.20 (8), p.757-766

2003

Volltextzugriff (PDF)

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Blood, 2002-10, Vol.100 (8), p.2941-2949

2002

Volltextzugriff (PDF)

Selective inhibition of primitive hemopoietic colony-forming cells by an extract from normal marrow : comparison with transforming growth factor-β

Experimental hematology, 1991-05, Vol.19 (4), p.245-249

1991

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(93)

Sprache

Englisch
(91)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(52)
Humans
(31)
Biological And Medical Sciences
(26)
Female
(19)
Male
(19)
Medical Sciences
(19)
Animals
(17)
Adult
(14)
Mice
(13)
Middle Aged
(12)
Aged
(11)
Hematology
(11)
Hematology, Oncology And Palliative Medicine
(9)
Radiology
(9)
Molecular Sequence Data
(8)
Amino Acid Sequence
(7)
Base Sequence
(7)
Cell Division - Drug Effects
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Irish Journal Of Medical Science
(11)
Brachytherapy
(9)
Blood
(8)
The Journal Of Immunology
(5)
Bmj
(3)
British Medical Journal
(3)
The Lancet
(3)
The journal Of Immunology/the journal Of Immunology
(3)
Advances In Limnology
(2)
Aids
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways

FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)

dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal

Optical imaging of bilingual cortical representations. Case report

Interleukin‐3, granulocyte‐macrophage colony stimulating factor and interleukin‐5 transduce signals through two STAT5 homologs

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial

Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5

Signaling Pathways Activated in a Unique Mast Cell Line Where Interleukin-3 Supports Survival and Stem Cell Factor Is Required for a Proliferative Response

Characterization of optical intrinsic signals and blood volume during cortical spreading depression

Optical intrinsic signal imaging in a rodent seizure model

Purinoceptor activation of chloride transport in cystic fibrosis and CFTR‐transfected pancreatic cell lines

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

Investigation of the Molecular Mechanisms Underlying Growth Factor Synergy: The Role of ERK 2 Activation in Synergy

Self-consciousness and the Psoriatic Personality: Considering Updike and Potter

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12R beta 1 and a Novel Cytokine Receptor Subunit, IL-23R

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Selective inhibition of primitive hemopoietic colony-forming cells by an extract from normal marrow : comparison with transforming growth factor-β

Suchergebnisse filtern